- Home
- JPI vs NYXH Comparison
JPI vs NYXH Comparison
Compare JPI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- NYXH
- Stock Information
- Founded
- JPI 2012
- NYXH 2009
- Country
- JPI United States
- NYXH Belgium
- Employees
- JPI N/A
- NYXH N/A
- Industry
- JPI Finance Companies
- NYXH Medical/Dental Instruments
- Sector
- JPI Finance
- NYXH Health Care
- Exchange
- JPI Nasdaq
- NYXH Nasdaq
- Market Cap
- JPI 288.1M
- NYXH 290.9M
- IPO Year
- JPI N/A
- NYXH 2021
- Fundamental
- Price
- JPI $20.43
- NYXH $7.49
- Analyst Decision
- JPI
- NYXH Strong Buy
- Analyst Count
- JPI 0
- NYXH 4
- Target Price
- JPI N/A
- NYXH $14.50
- AVG Volume (30 Days)
- JPI 54.7K
- NYXH 47.0K
- Earning Date
- JPI 01-01-0001
- NYXH 08-18-2025
- Dividend Yield
- JPI 6.15%
- NYXH N/A
- EPS Growth
- JPI N/A
- NYXH N/A
- EPS
- JPI N/A
- NYXH N/A
- Revenue
- JPI N/A
- NYXH $4,716,818.00
- Revenue This Year
- JPI N/A
- NYXH $209.22
- Revenue Next Year
- JPI N/A
- NYXH $219.37
- P/E Ratio
- JPI N/A
- NYXH N/A
- Revenue Growth
- JPI N/A
- NYXH N/A
- 52 Week Low
- JPI $16.02
- NYXH $5.55
- 52 Week High
- JPI $19.12
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- JPI 48.00
- NYXH 47.38
- Support Level
- JPI $20.32
- NYXH $6.90
- Resistance Level
- JPI $20.70
- NYXH $7.60
- Average True Range (ATR)
- JPI 0.18
- NYXH 0.34
- MACD
- JPI -0.01
- NYXH -0.06
- Stochastic Oscillator
- JPI 31.39
- NYXH 40.14
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.